Abstract
Assessing the status of malaria transmission in endemic areas becomes increasingly challenging as countries approach elimination and infections become rare. Here, we evaluated the use of multiplex antibody response data to malaria-specific antigens to classify recent and historical infections of differentially exposed populations in three provinces in the Philippines. We utilized samples (n=9132) from health-facility based cross-sectional surveys in Palawan (ongoing malaria transmission), Occidental Mindoro (limited transmission), and Bataan (no transmission) and quantified antibody responses against 8 Plasmodium falciparum and 6 P. vivax-specific antigens. Different statistical and machine learning analytical methods were used to examine associations between antigen-specific antibody responses with malaria incidence, and the ability to predict recent or historical exposure. Consistent with the provinces’ endemicity status, antibody levels and seroprevalence were consistently highest in Palawan and lowest in Bataan. A machine learning (ML) approach (Random Forest model) using identified responses to 4 antigens (PfGLURP R2, Etramp5.Ag1, GEXP18 and PfMSP119) gave better predictions for P. falciparum infection (positive by microscopy, RDT and/or PCR) or likely recent exposure in Palawan (AUC: 0.9591, CI 0.9497-0.9684) than mixture models calculating seropositivity to individual antigens. Meanwhile, employing the same ML approaches for the vivax-specific antigens did not improve predictions for recent P. vivax infections. Still, the antigen panel was overall able to confirm the absence of recent exposure to P. falciparum and P. vivax in both Occidental Mindoro and Bataan through single and ensemble ML approaches. Seroprevalence and seroconversion rates based on cumulative exposure markers AMA1 and MSP119 showed accurate trends of historical P. falciparum and P. vivax transmission in the 3 sites. Our study emphasizes the utility of serological markers in predicting recent and historical exposure in a sub-national elimination setting, establishes baseline antibody data for monitoring risk in malaria-endemic areas in the Philippines, and also highlights the potential use of machine learning models using multiplex antibody responses to accurately assess the malaria transmission status of countries aiming for elimination.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Newton Fund, Philippine Council for Health Research and Development, and UK Medical Research Council through funding received for ENSURE: Enhanced surveillance for control and elimination of malaria in the Philippines (MR/N019199/1). This work is also supported by the Nagasaki University ’Doctoral Program for World-leading Innovative and Smart Education’ for Global Health, ’Global Health Elite Programme for Building a Healthier World’.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed and approved by the Research Institute for Tropical Medicine Institutional Review Board (RITM IRB 2016-04) and London School of Hygiene and Tropical Medicine (LSHTM) Research Ethics Committee (11597).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data analyzed in this study are available from authors upon reasonable request and with permission of relevant institutional review boards.